Receipt date: 03/01/29 0

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

 Application Number
 10555860

 Filling Date
 2005-11-01

 First Named Inventor
 Christopher P. Holmes

 Art Unit
 1654

 Examiner Name
 J. R. Kosack

 Attorney Docket Number
 04279/100M213-US1

					U.S.F	PATENTS				
Examiner Initial*	ner Cite No Patent Number		Kind Code ¹			Name of Patentee or A of cited Document		Pages,Columns,Lines who Relevant Passages or Rel Figures Appear		
	1									
If you wisl	to ac	dd additional U.S. Pate	ent citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS			
Examiner Initial*	Cite I	No Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	to ac	dd additional U.S. Pub	lished Ap					d butto	on.	
				FOREIC	N PAT	ENT DOCUM	ENTS			_
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ² i		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1									
If you wis	h to a	L dd additional Foreign I	Patent Do	cument	citation	information pl	lease click the Add	butto	n	
			NOI	N-PATE	NT LITE	RATURE DO	CUMENTS			
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5		

	Application Number		10555860		
	Filing Date		2005-11-01		
INFORMATION DISCLOSURE	First Named Inventor Christopher P. Holmes				
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1654		
(Not for submission under 37 CFR 1.99)	Examiner Name	J. R.	Kosack		
	Attorney Docket Numb	er	04279/100M213-US1		

	1	Dubowchik et al.: "Doxorubicin Immunoconjugates Containing Bivalent Lysosomally-Cleavable Dipeptide Linkages" Bioorganic & Medicinal Chemistry Letters 12 (2002) pgs. 1529-1532.					
If you wish	to ad	d additio	onal non-patent literature document citati	ion information please click the Add b	outton		
			EXAMINER	SIGNATURE			
Examiner Signature		ure	/Andrew D. Kosar/	Date Considered	06/28/2010		
*EXAMINE	ER: Ini	tial if ref	erence considered, whether or not citation and not considered. Include copy of	on is in conformance with MPEP 609 of this form with next communication	. Draw line through a to applicant.		

See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.